# US 2015/0104382 A1 · Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104382 A1
- Document ID: US20150104382A1
- Status: Published application
- Kind: A1
- Application number: 14/520,962
- Filed: 2014-10-22
- Published: 2015-04-16
- Earliest claimed: 2000-03-27
- Assignees: Thomas Jefferson University
- Applicants: Thomas Jefferson University
- Inventors: Scott A. Waldman; Jason Park; Stephanie Schulz
- Web page: https://patentgrep.com/patent/US20150104382A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 51/1075: {the antibody being against an enzyme}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/40: against enzymes
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/5753: of the stomach or small intestine
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/158: Expression markers
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal cancer are disclosed.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method of treating an individual suspected of suffering from primary and/or metastatic stomach or esophageal cancer comprising the steps of administering to said individual a therapeutically effective amount of a composition comprising:
an antibody which a) binds to the protein encoded by SEQ ID NO:1, and b) is conjugated to therapeutic agent selected from the group consisting of: chemotherapeutics, radiotherapeutic agents and toxins.

### Claim at position 3

31-34. (canceled)

### Claim 35 (depends on 30)

The method of claim 30, wherein said therapeutic agent is a chemotherapeutic.

### Claim 36 (depends on 35)

The method of claim 35, wherein said therapeutic agent is a chemotherapeutic agent selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, 1,4-benzoquinone derivatives, macromomycin, nitroimidazole, metronidazole, and misonidazole.

### Claim 37 (depends on 30)

The method of claim 30, wherein said therapeutic agent is a toxin.

### Claim 38 (depends on 37)

The method of claim 37, wherein said therapeutic agent is a toxin selected form the group consisting of trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin and purothionin.

### Claim 39 (depends on 30)

The method of claim 30 wherein said therapeutic agent is a radiotherapeutic agent.

### Claim 40 (depends on 39)

The method of claim 39, wherein said therapeutic agent is a radiotherapeutic agent selected from the group consisting of 47Sc, 67Cu, 90Y, 109Pd, 123I, 125I, 131I, 186Re, 188Re, 99Au, 211At, 212Pb, 212B, 32P and 33P, 71Ge, 77As, 103Pb, 105Rh, 111Ag, 119Sb, 121Sn, 131Cs, 43Pr, 161Tb, 177Lu, 191Os, 193MPt, 197Hg, 43K, 52Fe, 57Co, 67Cu, 67Ga, 68Ga, 77Br, 81Rb/81MKr, 87MSr, 99MTc, 111In, 113MIn, 127Cs, 129Cs, 132I, 197Hg, 203Pb and 206Bi.

### Claim 41 (depends on 30)

The method of claim 30, wherein said composition is administered to said individual by injection.

### Claim 42 (depends on 30)

The method of claim 30, wherein said composition is administered to said individual intravenously.

### Claim 43 (depends on 30)

The method of claim 30, wherein said individual has been diagnosed as having primary esophageal cancer.

### Claim 44 (depends on 30)

The method of claim 30, wherein said individual has been diagnosed as having primary stomach cancer.

### Claim 45 (depends on 30)

The method of claim 30, wherein said individual has been diagnosed as having metastatic esophageal cancer.

### Claim 46 (depends on 30)

The method of claim 30, wherein said individual has been diagnosed as having metastatic stomach cancer.

### Claim 47

A method of treating an individual suspected of suffering from primary and/or metastatic stomach or esophageal cancer comprising the steps of administering to said individual a therapeutically effective amount of a composition comprising: an antibody which a) binds to the protein encoded by SEQ ID NO:1, and b) is conjugated to therapeutic agent selected from the group consisting of: compounds that cause cell death, compounds that inhibit cell division, and compounds that induce cell differentiation.

### Claim 48 (depends on 47)

The method of claim 47, wherein said composition is administered to said individual by injection.

### Claim 49 (depends on 47)

The method of claim 47, wherein said composition is administered to said individual intravenously.

### Claim 50 (depends on 47)

The method of claim 47, wherein said individual has been diagnosed as having primary esophageal cancer.

### Claim 51 (depends on 47)

The method of claim 47, wherein said individual has been diagnosed as having primary stomach cancer.

### Claim 52 (depends on 47)

The method of claim 47, wherein said individual has been diagnosed as having metastatic esophageal cancer.

### Claim 53 (depends on 47)

The method of claim 47, wherein said individual has been diagnosed as having metastatic stomach cancer.
